Stockreport

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Context Therapeutics Inc.  (CNTX) 
PDF CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will conti [Read more]